Medication‑Induced Vasomotor Symptoms (Hot Flashes and Night Sweats)

Antidepressants as Primary Offenders

• Fluoxetine (high‑dose SSRI) frequently causes sweating, hot flashes, and other thermoregulatory disturbances; the risk rises with doses around 60 mg. 1
• SSRIs, including fluoxetine, commonly produce adverse effects such as sweating, tremor, nervousness, insomnia or somnolence, and dizziness. 1
• Bupropion (noradrenergic stimulant) is “activating” and should be avoided in patients prone to agitation; it does not alleviate hot flashes and may worsen them. 1
• Concurrent use of fluoxetine and bupropion can synergistically intensify hot flashes and night sweats. 1

Other Medications Contributing to Vasomotor Symptoms

• Methylphenidate (stimulant) taken later in the day can exacerbate nighttime sweating; early‑morning dosing is recommended to minimize this effect. 1
• Naltrexone (opioid antagonist) is a less likely contributor to hot flashes compared with the antidepressants, but still warrants consideration. 1

Medications Unlikely to Cause or That May Reduce Symptoms

• Combined estrogen‑progestin contraceptives (e.g., norethindrone/ethinyl estradiol) are expected to reduce hot flashes rather than provoke them. 2
• Systemic absorption of inhaled bronchodilators (e.g., albuterol) and inhaled corticosteroids (e.g., fluticasone) is minimal at therapeutic doses, and they are not linked to vasomotor symptoms. 1

Evidence‑Based Pharmacologic Options When Symptoms Persist

Practical Management Recommendations

• Re‑evaluate the necessity of dual antidepressant therapy; consider discontinuing bupropion first if only one agent is required. 1
• If antidepressant treatment is still needed, switching to mirtazapine may address depressive symptoms and hot flashes simultaneously. 1
• When adjusting medications, taper fluoxetine or bupropion gradually over 10–14 days to avoid withdrawal‑related worsening of hot flashes and mood instability. 1

All statements are derived from peer‑reviewed sources and reflect the strength of evidence indicated in the original citations.

Medication-Induced Hot Flashes

Introduction to Medication-Induced Hot Flashes

• Duloxetine, an SNRI, can cause hot flashes as a side effect and is also used to treat hot flashes in some patients, according to the National Comprehensive Cancer Network 3, 4
• The mechanism behind SNRI-induced hot flashes involves alterations in serotonin and norepinephrine neurotransmission, which can affect thermoregulatory centers, as reported in the Annals of Oncology 5

Treatment Options for Hot Flashes

• Gabapentin (900 mg/day) can reduce hot flash severity by 46% compared to 15% with placebo, as recommended by the National Comprehensive Cancer Network 3, 4
• Venlafaxine (37.5-75 mg/day) can significantly reduce hot flash frequency and severity, according to the National Comprehensive Cancer Network 3, 4
• Clonidine (0.1 mg/day) may be useful for mild to moderate hot flashes, as reported in the Annals of Oncology and the National Comprehensive Cancer Network 4, 5
• Non-pharmacologic approaches, such as acupuncture, exercise/physical activity, yoga, and cognitive behavioral therapy, may help manage hot flashes, as suggested by the National Comprehensive Cancer Network 4
• Weight loss if overweight or obese can reduce hot flash symptoms, according to the National Comprehensive Cancer Network 4

Clinical Considerations for Hot Flash Treatment

• When selecting treatment for hot flashes, consider side effect profiles, with SNRIs/SSRIs having 10-20% discontinuation rates due to side effects versus 10% for gabapentin, as reported in the Annals of Oncology 5, 6
• Onset of action is an important consideration, with most pharmacologic treatments working rapidly (within 1 week), according to the Annals of Oncology 5, 6
• Drug interactions, such as CYP2D6 inhibition with paroxetine and tamoxifen, should be considered when choosing a treatment, as recommended by the National Comprehensive Cancer Network 4
• Comorbidities, such as depression or neuropathic pain, can influence treatment choice, with SNRIs/SSRIs preferred for depression and gabapentin preferred for neuropathic pain, as reported in the Annals of Oncology 5, 6